tirzepatide and asthma medication Dual GIPR GLP‐1R agonist inhibits aeroallergen‐induced allergic airway inflammation in mouse model of obese - Toki - 2023 - Clinical & Experimental Allergy Can you take Mounjaro with

Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events

Effects can be observed in stages

Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia

The involvement of the dopamine reward pathway in modulating food and alcohol consumption 15 could explain why semaglutide is beneficial in reducing food consumption 16 and in animal models reducing alcohol and other drug consumption 5